Extended Data Fig. 7: Levels of circulating and intratumoral CD8⁺PD-1⁺ and T_REG cells in HR⁺ BC patients.

a, Progression-free survival (PFS) curves for patients with HR⁺ BC treated with palbociclib (P) plus hormonotherapy (HT) stratified based on the median abundance of circulating CD4⁻CD8⁻ T cells (at baseline) in high ( ≥ median; n = 27) and low ( < median; n = 25). Data from patients from cohort #3 (n = 29) and cohort #4 (n = 23) were pooled. P value determined by Log-rank test is reported. b, Correlations between the number of circulating IL7R⁺ γδ T cells and CD4⁺FOXP3⁺CD25⁺ regulatory T (T_REG) cells or CD8⁺PD-1⁺ T cells in longitudinal blood samples (n = 60 samples in total) harvested from n = 24 HR⁺ BC patients at baseline, after 3 months of treatment and at relapse, as in Fig. 5h, left panel. P (by two-sided Spearman’s rank correlation test) and R (Spearman’s rank correlation coefficients) values are reported. c, Ulcerative colitis tissue section stained for the simultaneous detection of TCRγ/δ, CD8, CD4, FOXP3, PD-1, pan-CK and nucleus (DAPI) used as positive control for the staining of HR⁺ tumor specimens. Scale bar, 100 μm. For representative images of HR⁺ breast tumors and quantification of γδ T cells see Fig. 5i. d, Quantification of CD8⁺PD-1⁺ T cells, CD4⁺ T cells, and CD4⁺FOXP3⁺ T_REG cells in paired HR⁺ tumor biopsies collected at baseline (n = 8) and after disease progression on P plus HT (n = 8). P values (by two-tailed paired t-test) were all non-significant.

Source data